Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Role of circulating tumor DNA (ctDNA) in locally advanced (LA) and metastatic urothelial cancer (mUC). Clinical features of patients with malignant lesions detected by BLC only (A) and those with risk ...
GARDNER, Mass., Dec. 4, 2023 /PRNewswire/ -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense / ...
A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn't come back, researchers report. People who've gotten surgery for high-risk ...
GARDNER, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense ...
Accurate documentation of lesions during transurethral resection of bladder tumors (TURBT) is essential for precise diagnosis, treatment planning, and follow-up care. However, optimizing schematic ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results